Omeros Commences Initial Public Offering of Common Stock

SEATTLE, Sept. 18 /PRNewswire-FirstCall/ -- Omeros Corporation today announced
the launch of its initial public offering of 6.82 million shares of its common
stock. Omeros is a clinical-stage biopharmaceutical company committed to
discovering, developing and commercializing products focused on inflammation
and disorders of the central nervous system.

The estimated price range for the initial public offering is $10.00 to $12.00
per share. Omeros has applied to have the shares of common stock listed on
The NASDAQ Global Market under the ticker symbol "OMER." The underwriters
have the option to purchase up to an additional 1.02 million shares to cover
over-allotments, if any. All of the shares of common stock will be offered by
Omeros.

Omeros intends to use the net proceeds of the offering to fund the completion
of its Phase 3 clinical trials of OMS103HP, its lead product candidate being
evaluated for use during arthroscopic surgery to improve postoperative joint
function and reduce postoperative pain, as well as the potential launch and
commercialization of OMS103HP. The Company also intends to use the net
proceeds to fund the development of its other product candidates in the
clinic, OMS302 for ophthalmology and OMS201 for urology, and the development
of its pipeline of preclinical programs.

Deutsche Bank Securities Inc. will be acting as the sole book-running manager.
Wedbush PacGrow Life Sciences will be acting as the co-lead manager, Canaccord
Adams Inc. and Needham & Company, LLC will be acting as co-managers, and
Chicago Investment Group, LLC and National Securities Corporation will be
acting as junior co-managers. The offering will be made only by means of a
prospectus.

Copies of the preliminary prospectus may be obtained by contacting: Deutsche
Bank Securities Inc. by mail, Attn: Prospectus Department, 100 Plaza One,
Floor 2, Jersey City, NJ 07311, by telephone at (800)-503-4611 or by email:
prospectusrequest@list.db.com.

A registration statement relating to these securities has been filed with the
Securities and Exchange Commission but has not yet become effective. These
securities may not be sold nor may offers to buy be accepted prior to the time
that the registration statement becomes effective. This press release shall
not constitute an offer to sell or the solicitation of an offer to buy, nor
shall there be any sale of these securities in any state or jurisdiction in
which such offer, solicitation, or sale would be unlawful prior to
registration or qualification under the securities laws of any such state or
jurisdiction.

About Omeros Corporation

Omeros Corporation is a clinical-stage biopharmaceutical company committed to
discovering, developing and commercializing products focused on inflammation
and disorders of the central nervous system. Omeros' most clinically advanced
product candidates are derived from its proprietary PharmacoSurgery((TM))
platform designed to improve clinical outcomes of patients undergoing
arthroscopic, ophthalmological, urological and other surgical and medical
procedures. Omeros has four ongoing PharmacoSurgery((TM)) clinical development
programs, and its lead product candidate, OMS103HP, is being evaluated in
Phase 3 clinical trials for use during arthroscopic surgery to improve
postoperative joint function and reduce postoperative pain. Omeros is also
building a diverse pipeline of preclinical programs targeting inflammation and
central nervous system disorders.

Forward-looking Statements

This press release contains "forward-looking statements." These statements
include, but are not limited to, those regarding Omeros' proposed initial
public offering and expectations regarding its clinical development activities
and the clinical benefits of its product candidates. These forward-looking
statements are based on the current intent and expectations of the management
of Omeros. These statements are not guarantees of future performance and
involve risks and uncertainties that are difficult to predict. Omeros' actual
results and the timing and outcome of events may differ materially from those
expressed in or implied by the forward-looking statements because of risks
associated with Omeros' clinical development activities, regulatory oversight,
intellectual property rights and other risks. Omeros undertakes no obligation
to update any forward-looking or other statements in this press release,
whether as a result of new information, future events or otherwise.

SOURCE Omeros Corporation

Susan Neath for Omeros Corporation, +1-212-213-0006